Re-Pharm Identifies Novel Anti-Inflammatory Activity for Existing Compound
News Feb 11, 2015
Re-Pharm has announced the identification of RP0217 as an effective new anti-inflammatory agent.
RP0217 is an existing drug which is widely prescribed for non-inflammatory conditions. The identification of this novel anti-inflammatory activity creates the opportunity to develop new non-steroidal approaches to the treatment of a variety of disease indications.
“Re-Pharm is dedicated to re-purposing compounds to address areas of unmet medical need,” says Dr Alan Rothaul, CSO at Re-Pharm. “Our streamlined method made it possible to move efficiently through pharmacological assessment, computational chemistry work and initial testing in order to demonstrate novel anti-inflammatory activity for an existing drug.”
“We are delighted with the discovery of RP0217 and look forward to its progression through clinical trials,” says Dr Robert Scoffin, CEO at Re-Pharm. “The filing of our first patents represents a significant validation of Re-Pharm’s approach to re-profiling and I look forward to many similar future successes.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE